STOK Latest Press Releases

-- December 16, 2025 --

Stoke Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4) Business Wire 4:01 PM

-- December 5, 2025 --

Stoke Therapeutics and Biogen Present Data that Further Support the Disease-Modifying Potential of Zorevunersen, an Investigational Medicine for the Treatment of Dravet Syndrome, at the 2025 American Epilepsy Society (AES) Annual Meeting Business Wire 9:00 AM

Biogen and Stoke Therapeutics Present Data that Further Support the Disease-Modifying Potential of Zorevunersen, an Investigational Medicine for the Treatment of Dravet Syndrome, at the 2025 American Epilepsy Society (AES) Annual Meeting Globe Newswire 9:00 AM

-- December 1, 2025 --

Biogen and Stoke Therapeutics Announce Presentations at the 2025 American Epilepsy Society Annual Meeting Globe Newswire 7:30 AM

Stoke Therapeutics and Biogen Announce Presentations at the 2025 American Epilepsy Society Annual Meeting Business Wire 7:30 AM

-- November 18, 2025 --

Stoke Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4) Business Wire 4:01 PM

-- November 17, 2025 --

Stoke Therapeutics and Biogen Announce Publication of Two-Year Natural History Data Demonstrating the Severity of Dravet Syndrome, Including Frequent Seizures and Significant Cognitive and Behavioral Impairments Business Wire 7:30 AM

Biogen and Stoke Therapeutics Announce Publication of Two-Year Natural History Data Demonstrating the Severity of Dravet Syndrome, Including Frequent Seizures and Significant Cognitive and Behavioral Impairments Globe Newswire 7:30 AM

-- November 5, 2025 --

Stoke Therapeutics to Present at the Guggenheim 2nd Annual Healthcare Innovation Conference Business Wire 4:01 PM

-- November 4, 2025 --

Stoke Therapeutics Reports Third Quarter 2025 Financial Results and Provides Business Updates Business Wire 4:01 PM

-- October 30, 2025 --

Stoke Therapeutics to Host Webcast and Conference Call to Discuss Third Quarter 2025 Business and Financial Updates Business Wire 4:30 PM

-- October 20, 2025 --

Stoke Therapeutics Presents Two-Year Natural History Data from Patients with Autosomal Dominant Optic Atrophy (ADOA) Business Wire 7:30 AM

-- October 16, 2025 --

Stoke Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4) Business Wire 4:30 PM

-- October 9, 2025 --

Stoke Therapeutics and Biogen Present New Data at the 54th Child Neurology Society (CNS) Annual Meeting that Support the Potential of Zorevunersen as a Disease-Modifying Medicine for Dravet Syndrome Business Wire 4:30 PM

Biogen and Stoke Therapeutics Present New Data at the 54th Child Neurology Society (CNS) Annual Meeting that Support the Potential of Zorevunersen as a Disease-Modifying Medicine for Dravet Syndrome Globe Newswire 4:30 PM

-- October 6, 2025 --

Stoke Therapeutics Appoints Ian F. Smith as Chief Executive Officer Business Wire 7:30 AM

-- September 16, 2025 --

Stoke Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4) Business Wire 4:30 PM

-- September 2, 2025 --

Stoke Therapeutics and Biogen Present Data at the 36th International Epilepsy Congress that Support the Potential for Zorevunersen to be the First Disease-Modifying Medicine for Dravet Syndrome Business Wire 7:00 AM

Biogen and Stoke Therapeutics Present Data at the 36th International Epilepsy Congress that Support the Potential for Zorevunersen to be the First Disease-Modifying Medicine for Dravet Syndrome Globe Newswire 7:00 AM

-- August 28, 2025 --

Stoke Therapeutics to Present at Upcoming Investor Conferences in September 2025 Business Wire 4:30 PM

-- August 25, 2025 --

Stoke Therapeutics and Biogen Announce Presentations of Clinical Data from Studies of Zorevunersen for the Potential Treatment of Dravet Syndrome at the 36th International Epilepsy Congress Business Wire 7:00 AM

Biogen and Stoke Therapeutics Announce Presentations of Clinical Data from Studies of Zorevunersen for the Potential Treatment of Dravet Syndrome at the 36th International Epilepsy Congress Globe Newswire 7:00 AM

-- August 18, 2025 --

Stoke Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4) Business Wire 4:30 PM

SHAREHOLDER ALERT: Purcell & Lefkowitz LLP Announces Shareholder Investigation of Stoke Therapeutics, Inc. (NASDAQ: STOK) PRNewswire 8:45 AM

-- August 12, 2025 --

Stoke Therapeutics Reports Second Quarter 2025 Financial Results and Provides Business Updates Business Wire 4:01 PM

-- August 11, 2025 --

Stoke Therapeutics and Biogen Announce First Patient Dosed in Phase 3 EMPEROR Study of Zorevunersen, a Potential Disease-Modifying Treatment for Dravet Syndrome Business Wire 7:00 AM

Biogen and Stoke Therapeutics Announce First Patient Dosed in Phase 3 EMPEROR Study of Zorevunersen, a Potential Disease-Modifying Treatment for Dravet Syndrome Globe Newswire 7:00 AM

-- August 7, 2025 --

Stoke Therapeutics to Host Webcast and Conference Call to Discuss Second Quarter 2025 Business and Financial Updates Business Wire 7:00 AM

-- August 6, 2025 --

Stoke Therapeutics to Present at the Canaccord Genuity 45th Annual Growth Conference Business Wire 4:30 PM